Research
Hormonal
GLP-1 and GIP/GLP-1 agonists improve heart failure with preserved ejection fraction (HFpEF) symptoms and functional capacity in obese patients, independent of diabetes status.
If you have obesity and heart failure with preserved ejection fraction, discuss GLP-1 agonists with your cardiologist. They can significantly improve your heart failure symptoms, exercise capacity, and quality of life.
StrongSupportsVERY_HIGH confidence
The STEP-HFpEF trial... evaluated weekly semaglutide 2.4 mg vs. placebo in 529 patients with HFpEF and obesity... KCCQ-CSS improved by +16.6 vs. +8.7 with placebo... Weight decreased by –13.3% vs. −2.6%.
Why this rating
Based on randomized controlled trials (STEP-HFpEF, STEP-HFpEF DM, SUMMIT) with significant improvements in functional capacity and symptoms.
Source
Pharmacological therapy in the obese patient: is it only a matter of fat loss?
Claudio Borghi et al. · European Heart Journal Supplements · 2026
DOI 10.1093/eurheartjsupp/suag029
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (semaglutide 2.4 mg) and dual GIP/GLP-1 agonists (tirzepatide) reduce major adverse cardiovascular events (MACE) in obese patients without diabetes, independent of weight loss alone.Strong
- GLP-1 and GIP/GLP-1 agonists reduce systemic inflammation (hsCRP, IL-6) and improve metabolic parameters (HbA1c, blood pressure, lipids) in obese patients, contributing to overall cardiovascular risk reduction.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →